Development trend analysis of ranolazine, based on bibliometrics

Area of Science:

• Pharmacology and Cardiovascular Research
• Bibliometrics and Scientometrics

Background:

• Ranolazine, an FDA-approved anti-anginal drug, has extensive research but faces clinical application challenges.
• Uncertainties in efficacy, safety, and expanded indications necessitate a current bibliometric analysis.
• Over 2000 papers highlight ranolazine's therapeutic potential across various fields.

Purpose of the Study:

• To conduct a bibliometric analysis of ranolazine research to identify trends and challenges.
• To optimize interdisciplinary strategies for ranolazine research and application.
• To provide insights for future research directions in ranolazine therapy.

Main Methods:

• Data sourced from the Science Citation Index Expanded (Web of Science Core Collection) as of September 1, 2025.
• Microsoft Excel used for data organization.
• Bibliometric analysis and visualization performed using WeiShengXin, CiteSpace, and VOSviewer.

Main Results:

• 1121 papers were analyzed, with the USA as the most productive country.
• Gilead Sciences and authors Belardinelli, L. and Chaitman, B.R. showed highest institutional and author output, respectively.
• Keywords like "efficacy," "ventricular arrhythmias," "impact," and "channels" remain highly influential.

Conclusions:

• Current research focuses on ranolazine's anti-anginal, electrophysiological, and anti-arrhythmic effects.
• Future research should explore ranolazine's neuroprotective and anti-tumor metastasis effects.
• Investigating ranolazine's impact on atrial fibrillation and diabetes patients is a key future direction.